[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628557":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":197,"collaborators":40,"id":199,"slug":40,"hasResults":200,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":40,"eligibilityCriteria":204,"healthyVolunteers":200,"sex":205,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":40,"studyType":211,"phases":212,"briefSummary":214,"conditions":215,"keywords":40,"overallStatus":54,"whyStopped":40,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Period 1: MK-8690","EXPERIMENTAL","Participants will receive MK-8690 via subcutaneous injection for 12 weeks.",[13],"Drug: MK-8690",{"label":15,"type":16,"description":17,"interventionNames":18},"Period 1: Placebo","PLACEBO_COMPARATOR","Participants will receive placebo via subcutaneous injection for 12 weeks.",[19],"Other: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Period 2: MK-8690","Participants who do not respond to treatment in Period 1 (regardless of treatment assignment in Period 1) will receive MK-8690 via subcutaneous injection for 12 weeks.",[13],{"label":25,"type":10,"description":26,"interventionNames":27},"Period 3: MK-8690","Participants who respond to treatment in either Period 1 or Period 2 will receive additional MK-8690 via subcutaneous injection for up to approximately 42 weeks.",[13],[29,36],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","MK-8690","Solution for subcutaneous injection",[9,21,25],[35],"PRA052",{"type":37,"name":38,"description":32,"armGroupLabels":39,"otherNames":40},"OTHER","Placebo",[15],null,[42],{"name":43,"affiliation":5,"role":44},"Medical Director","STUDY_DIRECTOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":40,"email":50},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[52,69,82,94,107,119,132,145,158,171,185],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Clinnova Research ( Site 1042)","RECRUITING","Anaheim","California","92805","United States",{"type":60,"coordinates":61},"Point",[62,63],-117.9145,33.83529,{"lat":63,"lon":62},[66],{"name":67,"role":48,"phone":68,"phoneExt":40,"email":40},"Study Coordinator","949-889-0249",{"facility":70,"status":54,"city":71,"state":72,"zip":73,"country":58,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Peak Gastroenterology Associates ( Site 1052)","Colorado Springs","Colorado","80907",{"type":60,"coordinates":75},[76,77],-104.82136,38.83388,{"lat":77,"lon":76},[80],{"name":67,"role":48,"phone":81,"phoneExt":40,"email":40},"719-636-1201",{"facility":83,"status":54,"city":84,"state":72,"zip":85,"country":58,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"South Denver Gastroenterology, PC ( Site 1068)","Englewood","80113",{"type":60,"coordinates":87},[88,89],-104.98776,39.64777,{"lat":89,"lon":88},[92],{"name":67,"role":48,"phone":93,"phoneExt":40,"email":40},"303-406-4288",{"facility":95,"status":54,"city":96,"state":97,"zip":98,"country":58,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Nature Coast Clinical Research ( Site 1045)","Inverness","Florida","34452",{"type":60,"coordinates":100},[101,102],-82.33037,28.83582,{"lat":102,"lon":101},[105],{"name":67,"role":48,"phone":106,"phoneExt":40,"email":40},"352-341-2100",{"facility":108,"status":54,"city":109,"state":97,"zip":110,"country":58,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)","Miami","33134",{"type":60,"coordinates":112},[113,114],-80.19366,25.77427,{"lat":114,"lon":113},[117],{"name":67,"role":48,"phone":118,"phoneExt":40,"email":40},"786-476-8790",{"facility":120,"status":54,"city":121,"state":122,"zip":123,"country":58,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Gastroenterology Associates of Central Georgia ( Site 1060)","Macon","Georgia","31201",{"type":60,"coordinates":125},[126,127],-83.6324,32.84069,{"lat":127,"lon":126},[130],{"name":67,"role":48,"phone":131,"phoneExt":40,"email":40},"478-464-2600",{"facility":133,"status":54,"city":134,"state":135,"zip":136,"country":58,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"University of Kansas Medical Center ( Site 1077)","Kansas City","Kansas","66160",{"type":60,"coordinates":138},[139,140],-94.62746,39.11417,{"lat":140,"lon":139},[143],{"name":67,"role":48,"phone":144,"phoneExt":40,"email":40},"913-588-6019",{"facility":146,"status":54,"city":147,"state":148,"zip":149,"country":58,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Tulane University School of Medicine ( Site 1073)","New Orleans","Louisiana","70112",{"type":60,"coordinates":151},[152,153],-90.07507,29.95465,{"lat":153,"lon":152},[156],{"name":67,"role":48,"phone":157,"phoneExt":40,"email":40},"504-988-5110",{"facility":159,"status":54,"city":160,"state":161,"zip":162,"country":58,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"BVL Research - Kansas ( Site 1054)","Liberty","Missouri","64068",{"type":60,"coordinates":164},[165,166],-94.41912,39.24611,{"lat":166,"lon":165},[169],{"name":67,"role":48,"phone":170,"phoneExt":40,"email":40},"816-222-4241",{"facility":172,"status":54,"city":173,"state":174,"zip":175,"country":176,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Wonju Severance Christian Hospital ( Site 1602)","Wŏnju","Kang-won-do","26426","South Korea",{"type":60,"coordinates":178},[179,180],127.94528,37.35139,{"lat":180,"lon":179},[183],{"name":67,"role":48,"phone":184,"phoneExt":40,"email":40},"+82 33 741 0505",{"facility":186,"status":54,"city":187,"state":40,"zip":188,"country":176,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Kangbuk Samsung Hospital ( Site 1601)","Seoul","03181",{"type":60,"coordinates":190},[191,192],126.9784,37.566,{"lat":192,"lon":191},[195],{"name":67,"role":48,"phone":196,"phoneExt":40,"email":40},"+82-2-2001-8556",{"type":198,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100628557",false,"NCT07463183","A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)","A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis","The main inclusion criteria include but are not limited to the following:\n\n* Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization\n* Has moderately to severely active UC\n* Has a weight ≥40 kg\n* Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC treatments\n* Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment\n* Has a current diagnosis of fulminant colitis and\u002For toxic megacolon\n* Has UC limited to the rectum\n* Has a current or impending need for colostomy or ileostomy\n* Has had a total proctocolectomy or partial colectomy\n* Has UC exacerbation requiring hospitalization within 2 weeks before Screening\n* Has any active infection as specified in the protocol\n* Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\n* Has evidence of active tuberculosis (TB) or meets TB exclusionary parameters\n* Has a history of cancer (except fully treated nonmelanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years before Randomization or has a history of colorectal cancer at any time\n* Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed\n* Has had major surgery within 3 months before Screening or has a major surgery (ie, surgical procedure requiring general anesthesia) planned during the study\n* Has received protocol-specified prohibited medications","ALL","18 Years","75 Years",{"count":209,"type":210},100,"ESTIMATED","INTERVENTIONAL",[213],"PHASE2","The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.",[216,217],"Colitis Ulcerative","Ulcerative Colitis","2026-07-01",{"date":220,"type":221},"2026-07-02","ACTUAL",{"date":223,"type":221},"2026-03-24",{"date":225,"type":210},"2028-12-21",{"name":5,"class":6},11]